Licensing

Licensing
Product Description

Top tier pharmaceutical companies, biotechs, diagnostics, medtech, healthcare IT and life science research companies, universities and technology transfer agencies have trusted​​ us to deliver the best licensing deals for their assets. 

PHARMAVENTURES LTD

  • GB
  • 2020
    On CPHI since
  • 25 - 49
    Employees
Company types
Consultancy

PHARMAVENTURES LTD

  • GB
  • 2020
    On CPHI since
  • 25 - 49
    Employees
Company types
Consultancy

More Products from PHARMAVENTURES LTD (2)

  • M&A

    Product M&A

    With over 29 years of experience and operating across all key life science sectors, PharmaVentures offers deep sector expertise to support your M&A and funding transactions.

    We support our clients with strategic advice and full end-to-end process management capabilities to achieve best outc...
  • Fundraising

    Product Fundraising

    Operating across all key life science sectors, PharmaVentures offers deep sector expertise to help you derive optimal value from your funding transactions.

    We support our clients with strategic advice and full end-to-end process management capabilities to achieve the best outcome from their strateg...

PHARMAVENTURES LTD resources (7)

  • Sponsored Content Size doesn’t matter: How smaller deals are shaping healthcare M&A

    Several mega-deals have made a splash in the pharma and life sciences industries over recent years – from AstraZeneca’s acquisition of Alexion for $39 billion to Gilead Sciences’ $21 billion purchase of Immunomedics. With ample capital available in the sector, it comes as no surprise that PwC forecasts M&A deals will reach $400 billion this year.  
  • Brochure PharmaVentures Corporate Brochure

    Download PharmaVentures' Corporate Brochure. 
  • Technical Data Termsheet Issue 33

    Vaccines, patents and supply. 
  • Whitepaper Deal Making in the Year of COVID-19

    In the Spring of 2020, during the early days of the COVID-19 pandemic when there were real fears of a global downturn, PharmaVentures predicted that despite the forthcoming challenges, licensing and partnering would remain steady during 2020. With the year behind us, we are revisiting our deal closing predictions to see if they have held true.
  • Video How is M&A Shifting the Pharma Manufacturing Landscape?

    Innovative manufacturing technologies are creating fresh deal-making opportunities for Pharma Manufacturers and CDMOs across both small and large molecule sectors, which are in turn transforming the pharma manufacturing landscape. Partnerships and mergers are a key tool for adding value to pharmaceutical companies; helping to navigate technological limitations, address portfolio challenges and chase innovation. This webinar, delivered in partnership with PharmaVentures, examines the trends and developments driving deal-making in the current market. Chaired by Dr Fintan Walton, CEO & Founder of PharmaVentures, the panel included: John P. FitzGerald, Senior Director, Business Development & Acquisitions, Abbvie Andreas Raabe, Managing Partner & Founder, Adragos Pharma William S. Marth, Managing Partner, North Ocean Ventures Jansen Jacob, Vice President, PharmaVentures Ozgur Akbulut, Director – Global Divestments and Contract Manufacturing Lead, Takeda
  • Webinar CPHI Webinar Series How is M&A Shifting the Pharma Manufacturing Landscape?

    What will this webinar address? Innovative manufacturing technologies are creating fresh deal-making opportunities for Pharma Manufacturers and CDMOs across both small and large molecule sectors, which are in turn transforming the pharma manufacturing landscape. Partnerships and mergers are a key tool for adding value to pharmaceutical companies; helping to navigate technological limitations, address portfolio challenges and chase innovation. This webinar, delivered in partnership with PharmaVentures, will examine the trends and developments driving deal-making in the current market. When you attend this webinar, you will discover: The key acquisition drivers for Pharma Manufacturers and CDMOs (tech, therapy areas, patent losses, portfolio challenges) What does the future look like? Prior to the COVID-19 pandemic, M&A activity in pharmaceuticals was soaring with $414 billion worth of deals in 2019 . What will the short to mid-term impact be on deal-making? How is ‘reshoring’ transforming the pharma manufacturing map and impacting Governments?
  • Webinar How Small/Mid-Size Firms are Shaping the Healthcare M&A Market

    What will this webinar address? Whilst the mega deals make the headlines, it is the smaller companies who are shaping the M&A landscape with their interesting and innovative deals. They have the drive and efficiencies that allow them to do deals more quickly. In this webinar, PharmaVentures brings its unique insight into the issues, challenges, and benefits of doing M&A deals amongst small to mid-sized Diagnostics, MedTech, CDMO & CRO companies. Join us to learn the answers to the following Why are strategic thinking and preparation key to success? How do you avoid failure in doing M&A? What are the key drivers for companies taking the M&A route? What are key lessons from selling and buying businesses? What negotiation tactics work? How important is the asset vs the people in acquiring a business?